In questa sessione di domande e risposte, Dr. Pawan Kumar Singh, Vice Chairman of Haemato-Oncology and Bone Marrow Transplant at Sharda Care Healthcity, Greater Noida, answers the most common questions patients and families ask about sickle cell anemia, from genetics and early diagnosis to pain management, gene therapy, and curative treatment options.
Guarda la conversazione completa:
Q: For someone newly diagnosed with sickle cell anemia and no medical background, how would you explain what it actually is?
Normally, red blood cells are disc-shaped. In sickle cell disease, an abnormal hemoglobin caused by a genetic mutation makes the red cells become sickle-shaped instead. These sickle-shaped cells clog small blood vessels, which is why patients experience such a wide range of symptoms.
Because of this vessel clogging, patients can experience pain crises, acute chest syndrome, stroke, and clotting in major vessels. Almost any organ in the body, from head to toe, can be affected by sickle cell disease.
Q: How common is sickle cell anemia globally, and which populations and regions are most affected?
Sickle cell disease is most common in malaria-endemic regions, since carrying the sickle cell trait offers a survival advantage against malaria. This is why the disease is more prominent in certain areas rather than others.
The highest prevalence is seen in Nigeria, followed by the Democratic Republic of Congo and other parts of central and eastern Africa. In India, it is more commonly seen in tropical areas such as Odisha. Rising case numbers are largely a reflection of population growth rather than the disease itself becoming more common.
Q: What is actually happening inside the body at a cellular level?
The red blood cells, which are normally disc-shaped, become sickle-shaped due to the genetic mutation. This abnormal shape clogs blood vessels, which can lead to pain crises, sequestration crises, strokes, and blockages in major blood vessels.
Environmental factors also play a role. African patients with sickle cell disease tend to be more symptomatic and more often require bone marrow transplant to cure the disease, while Indian patients are generally less symptomatic and less likely to need such high-end treatment. This is why maintaining good hydration and avoiding extremes of temperature is always recommended, since both cold and heat exposure can trigger a sickling crisis. Infections and low oxygen levels (hypoxia) are other significant risk factors.
Q: What is the difference between being a sickle cell carrier (trait) and having sickle cell disease?
Hemoglobin is a protein, and like any protein, it is formed by genes, in this case, two genes. If only one gene is affected, this is called sickle cell trait, or carrier status. If both genes are affected, this leads to sickle cell disease, also called sickle cell anemia.
Normal hemoglobin is referred to as HbA, and sickle hemoglobin as HbS. In lab reports, this often appears as "AS" or "SS." AS means carrier or trait (heterozygous), meaning one gene is normal and one is affected. SS means both genes are affected (homozygous), which is the full disease.
Q: How does inheritance work, and what is the chance of a child inheriting the disease if one or both parents carry the gene?
A child inherits one hemoglobin gene from each parent. If only one parent is a carrier, the child can at most be a carrier as well, with no disease risk. The concern arises when both parents are carriers. In that case, there is a 25 percent chance in each pregnancy that the child will inherit the disease.
Anyone with a family history, particularly couples living in sickle-cell-endemic areas, should know their carrier status before or early in a pregnancy, since this risk applies to every pregnancy, not just one.
Q: What are the earliest signs and symptoms parents should watch for, and at what age does the disease typically begin to show?
Symptoms generally begin to appear around 5 to 6 months of age. Before that point, a baby's hemoglobin is mostly fetal hemoglobin, which is unaffected by the condition. Around 5 to 6 months, this fetal hemoglobin shifts to adult hemoglobin, which in affected children means a shift to sickle hemoglobin.
Once this shift happens, symptoms such as excessive crying, failure to thrive, poor feeding, and paleness may appear. At that point, evaluation and diagnosis by a hematologist is needed. Not every diagnosed child will require a bone marrow transplant. Children are typically monitored for 1 to 2 years to assess how symptomatic the disease is before considering advanced treatment.
Q: What triggers a pain crisis (vaso-occlusive crisis), and what should a patient or family do when one begins?
Common triggers include infections, low oxygen states, physical stress, dehydration, and diarrheal episodes. A pain crisis presents as severe, generalized body pain, often severe enough to require opioid analgesics for control. Good hydration and prompt management of any underlying trigger, such as fever or infection, are essential and should be handled in a hospital setting when needed.
Per saperne di più: Sickle Cell Treatment Cost in India
Q: How is sickle cell disease diagnosed, and why does early diagnosis matter?
A simple test called HPLC (High-Performance Liquid Chromatography) is used to confirm the diagnosis based on symptoms. Once diagnosed, the focus shifts to preventing sickling episodes. Hydroxyurea is one of the most important medications for preventing painful crises, alongside maintaining good hydration and overall health.
Q: What is acute chest syndrome, and how is it treated?
Acute chest syndrome occurs when the blood vessels in the lungs become clogged by abnormal sickle-shaped red cells. It presents as severe breathlessness, low oxygen saturation, and chest infiltrates visible on X-ray. This is a serious condition that requires hospital admission, often in an ICU, with close monitoring.
Treatment typically includes hydroxyurea, steroids such as dexamethasone, and IV antibiotics to prevent secondary infections.
Q: When are blood transfusions recommended, and what are the risks of long-term use?
Blood transfusions are used to prevent crises, support patients undergoing surgical procedures, or manage complications directly. Transfusion works by diluting the percentage of sickle hemoglobin in the blood. Symptomatic patients often have an HbS percentage above 60 percent, and introducing normal blood reduces that percentage, which typically brings symptom relief.
Transfusions are indicated when hemoglobin drops significantly, before planned surgery, or during a painful or sequestration crisis.
Q: How do you approach pain management, both during a crisis and for chronic pain at home?
Hydroxyurea plays a central role in preventing painful episodes in the first place. For pain that does occur, treatment typically starts with non-steroidal anti-inflammatory drugs (NSAIDs), and if that isn't sufficient, moves to oral opioid analgesics at home. If pain remains uncontrolled, hospital admission for IV or subcutaneous opioid analgesics may be needed. Maintaining good hydration and keeping hemoglobin levels above 10 are also important parts of pain management.
Q: There has been a lot of excitement about gene therapy for sickle cell anemia. What does it involve?
Gene therapy was approved relatively recently, around 2023 to 2024, and is currently intended for patients over 18 years of age with significant symptoms. There are two approaches: one that directly corrects the defective hemoglobin gene, and another that works by inducing the production of fetal hemoglobin (HbF).
The process involves harvesting the patient's stem cells, making the required genetic modifications, giving the patient chemotherapy to clear existing bone marrow, and then reinfusing the modified stem cells. While early data has been encouraging, the treatment remains very costly and is not currently available in India, it is mostly accessible in the US and Europe.
Per saperne di più: Most Commponly Asked Question About Sickle Cell
Q: Where do you see sickle cell treatment heading in the next 5 to 10 years?
Prevention remains the most important focus, primarily through screening young couples for carrier status and offering prenatal diagnosis in every pregnancy. Preventing sickling crises through hydroxyurea and good hydration also remains essential.
There are newer disease-modifying therapies as well, including injectable medications such as crizanlizumab and voxelotor, which have shown good results in reducing sickling crises. Beyond that, bone marrow transplant and gene therapy remain the two options that can offer a permanent cure, allowing a child to be fully cured without long-term disease effects.
Q: What lifestyle changes and precautions can help reduce the frequency and severity of crises?
Hypoxia, stress, dehydration, and febrile illness or infection are the key triggers to be mindful of. Avoiding these as much as possible directly reduces the number of sickling episodes. Taking a daily hydroxyurea dose as prescribed is equally important, since some episodes can also occur spontaneously.
Q: Can young patients with sickle cell disease live a relatively normal life, including physical activity and travel?
An entirely "normal" life isn't guaranteed, but with the right precautions, including daily hydroxyurea, staying prepared with analgesics, and managing known triggers, patients can genuinely thrive. That said, spontaneous sickling crises can still occur even with good management, so ongoing vigilance remains important.
Q: What should a woman with sickle cell anemia know about pregnancy risk, and is genetic counseling necessary?
If both partners are carriers, there is a 25 percent risk of sickle cell disease in every pregnancy. Prenatal diagnosis can be performed around 10 weeks into pregnancy, allowing couples to understand whether the developing fetus is affected and make informed decisions about how to proceed. Genetic counseling is strongly recommended for any couple where both partners carry the trait.
Q: For patients in countries with limited or expensive sickle cell treatment, is traveling to India for care a realistic option?
Yes. India sees a significant number of medical tourism patients for sickle cell treatment, most commonly for bone marrow transplant, as well as for managing complications such as avascular necrosis of the hip, which sometimes requires intervento di sostituzione dell'anca. India's centers, particularly for trapianto di midollo osseo including haploidentical transplants for sickle cell disease, have good outcomes and strong clinical experience. This makes it a realistic and increasingly popular option for patients considering treatment abroad.
Q: How can patients or families reach your team for a consultation or second opinion?
Sharda Care Healthcity has a dedicated international patient department that assists with travel, accommodation, and treatment coordination. Patients can reach out with their medical details and questions to HOSPIDIO, and either the hospital team or the international care team will respond and guide them through a smooth treatment and travel process.
Chi siamo Dr. Pawan Kumar Singh
Dr. Pawan Kumar Singh is Vice Chairman of Haemato-Oncology and Bone Marrow Transplant at Sharda Care Healthcity, Greater Noida, with over 15 years of experience treating complex blood disorders, including leukemia, lymphoma, multiple myeloma, aplastic anemia, thalassemia, and sickle cell disease. He has performed over 1,000 bone marrow transplants, including matched sibling, matched unrelated donor, and haploidentical procedures.
Learn more about his practice and prenota una consulenza.
Considering sickle cell treatment in India? Hospidio connects international patients with leading hematologists and top-accredited hospitals across India, offering transparent pricing, treatment planning, and end-to-end travel support.
Blog recenti
Dr. Basim Parvez è un fisioterapista abilitato e consulente senior per i pazienti presso HOSPIDIO, in possesso di un MBA in gestione sanitaria. Grazie alla sua vasta esperienza clinica e a un approccio empatico, assiste i pazienti nel percorso di cura. Dr. Basim sfrutta inoltre il suo talento di scrittore per semplificare informazioni sanitarie complesse, consentendo ai pazienti di prendere decisioni consapevoli e promuovendo chiarezza e fiducia nel loro percorso medico.
Guneet Bhatia è la fondatrice di HOSPIDIO e un'esperta revisore di contenuti con una vasta esperienza nello sviluppo di contenuti medici, nella progettazione didattica e nel blogging. Appassionata della creazione di contenuti di grande impatto, eccelle nel garantire accuratezza e chiarezza in ogni articolo. Guneet ama intavolare conversazioni significative con persone di diverse origini etniche e culturali, arricchendo così la sua prospettiva. Nel tempo libero, si dedica alla famiglia, ascolta buona musica e si diverte a ideare soluzioni innovative con il suo team.